Clinical Usefulness of Non-Invasive Metabolic-Associated Fatty Liver Disease Risk Assessment Methods in Patients with Polycystic Ovary Syndrome in Relation to MRI Examination with the Ideal IQ Sequence

The study conducted on 49 women with Polycystic Ovary Syndrome (PCOS) found that Lipid Accumulation Product (LAP) and Free Androgens Index (FAI) are effective non-invasive methods for assessing the risk of Metabolic-Associated Fatty Liver Disease (MAFLD). A LAP value over 70.25 and a FAI value over 5.05 were associated with liver steatosis, with women having LAP > 70.25 and FAI > 5.05 at 4.07 to 80.38 and 3.04 to 45.27 times higher risk of liver steatosis respectively. However, Sex Hormone-Binding Globulin (SHBG), a component of FAI, was not a significant predictor of liver steatosis. These findings suggest that LAP and FAI can be used to diagnose liver steatosis in women with PCOS, where MAFLD prevalence is around 30-70%.